Auxilium Pharmaceuticals, Inc.

Discussion in 'Men's Economics' started by Michael Scally MD, Apr 30, 2014.

  1. Michael Scally MD

    Michael Scally MD Doctor of Medicine

    Auxilium Pharmaceuticals, Inc. Lowers 2014 Financial Guidance
    Auxilium Pharmaceuticals, Inc. Lowers 2014 Financial Guidance - WSJ.com


    CHESTERBROOK, Pa., April 29, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that it is reducing its financial guidance for the full year 2014 due primarily to lower-than-expected revenues from Testim(R) testosterone gel.
     
  2. Michael Scally MD

    Michael Scally MD Doctor of Medicine

    Trimel Pharmaceuticals Announces Positive Phase II Results for Tefina™
    http://trimelpharmaceuticals.com/Ne...nnounces-Positive-Phase-II-Results-for-Tefina

    TORONTO (May 28, 2014) – Trimel Pharmaceuticals Corporation (TSX: TRL) announced today top-line results of its Phase II clinical trial evaluating the efficacy and safety of Tefina™, a “use-as-required” testosterone nasal gel for the treatment of Female Orgasmic Disorder (FOD). FOD, also known as anorgasmia, is characterized by a delay, absence or reduced intensity of orgasm, causing clinically significant distress.

    The double-blind, placebo-controlled study enrolled 253 pre- and post-menopausal women experiencing acquired FOD in the United States, Canada and Australia. Participants were randomized to one of three dosage strengths (0.6 mg, 1.2 mg, 1.8 mg) or a placebo group and treated over the course of 84 days. The primary endpoint of the study was to compare the effects of the three dose strengths of Tefina™ nasal testosterone gel to placebo on the occurrence of orgasm. Secondary endpoints included the change from baseline in distress due to orgasmic disorder, change in sexual functioning and sexual event satisfaction. Safety and tolerability were also assessed.

    Tefina™ 0.6 mg led to a statistically significant increase in the average number of orgasms during the 84-day treatment period of 2.3 versus 1.7 for the placebo arm (p=0.0015). In addition, improvements in all of the secondary endpoints were observed; however, further analysis is underway to assess statistical significance. Tefina™ was found to be well-tolerated with no reported serious adverse events.
     
  3. Burrr

    Burrr Member AnabolicLab.com Supporter

    Man, I hope that wasn't 2.3 orgasms for the whole 84 days :(